European Commission warns about fake Acomplia sale
The European Commission has publicly issued a warning regarding the selling of fake Acomplia (rimonabant), the unapproved weight-loss drug over the internet.Read More...

Acomplia could promote weight loss and fight diabetes
Obesity is directly related to mortality as the dreaded disease can foster ailments ranging from cancer to heart failure, and it's a clear factor behind the growing epidemic of type 2 diabetes across the world and specifically in the U.S.Read More...

Acomplia can be used to combat cardiovascular disease
According to the research unveiled in Atlanta by the American College of Cardiology in a conference it has been discovered that Sanofi Aventis' drug rimonabant, branded as Acomplia, can be used to combat cardiovascular disease by suppressing patients' appetite, helping them lose weight as abdominal fat is considered a significant risk factor for heart disease.Read More...

Sanofi contemplates 'Zimulti' as another name for Acomplia
Acomplia's developer Sanofi-Aventis appears to be considering yet another name for a possible re-branding of the weight-loss drug which it is planning to bring to the U.S. market later this year by the name of Zimulti. Read More...

Prospects of an early FDA action on Acomplia dimmed
The Prospects of an early FDA decision on Acomplia (rimonabant) seems like a distant dream as the next meeting of the Endocrinologic and Metabolic Drugs Advisory Committee which had been set for August 2006, has been scrubbed, with no meeting even tentatively scheduled now until November 2006. Read More...

Is 'Celnec' the new name for Acomplia
If Acomplia's developer Sanofi-Aventis decides to change the weight-loss drug's name before bringing it to the U.S. market then there are possibilities that the brand name may be Celnec. Read More...